AI, Google and DeepMind

AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Google DeepMind CEO says 2025's the year we start popping pills AI helped invent
Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday.
Trials of drugs developed with AI could begin this year, Google DeepMind CEO says
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have
DeepMind expects clinical trials for AI-designed drugs this year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Google's DeepMind eyes clinical trials for AI-designed drugs in 2025 - report
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Roll over, Darwin: How Google DeepMind's 'mind evolution' could enhance AI thinking
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
Unbelievably Real AI Commercial Has No Actors, Locations, Or Sets
Good news for marketers... A demo car commercial created totally using AI is so realistic you won't believe it. Amazing ...
eWeek4h
Can AI Pass Humanity’s Ultimate Intelligence Test?
Can AI pass Humanity’s Last Exam? Discover the bold benchmark redefining artificial intelligence and its potential.
DeepMind’s new inference-time scaling technique improves planning accuracy in LLMs
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
Google rushed to sell AI tools to Israel’s military after Hamas attack
The company fulfilled requests from Israel’s military for more access to AI tools as it sought to compete with Amazon, ...
The Prompt: Inside Google's AI Innovation Engine
The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases ...
MIT Technology Review2d
The second wave of AI coding is here
A string of startups are racing to build models that can produce better and better software. They claim it’s the shortest ...
Nvidia's toughest competition might just be Alphabet - but there's a catch
Wall Street is always musing about alternatives to Nvidia Corp. One analyst just suggested a big name that's not often in the conversation.